Found: 22
Select item for more details and to access through your institution.
Reproducible lung protective effects of a TGFβR1/ALK5 inhibitor in a bleomycin‐induced and spirometry‐confirmed model of IPF in male mice.
- Published in:
- Physiological Reports, 2024, v. 12, n. 19, p. 1, doi. 10.14814/phy2.70077
- By:
- Publication type:
- Article
Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-10577-2
- By:
- Publication type:
- Article
Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 12, p. 6332, doi. 10.3390/ijms22126332
- By:
- Publication type:
- Article
Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
- Published in:
- PLoS ONE, 2024, v. 19, n. 4, p. 1, doi. 10.1371/journal.pone.0300809
- By:
- Publication type:
- Article
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis.
- Published in:
- Liver International, 2021, v. 41, n. 8, p. 1853, doi. 10.1111/liv.14888
- By:
- Publication type:
- Article
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.
- Published in:
- Liver International, 2020, v. 40, n. 11, p. 2860, doi. 10.1111/liv.14643
- By:
- Publication type:
- Article
Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-58059-7
- By:
- Publication type:
- Article
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-45178-z
- By:
- Publication type:
- Article
Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Paraoxonase‐2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non‐alcoholic steatohepatitis.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 19, p. 3717, doi. 10.1111/bph.16438
- By:
- Publication type:
- Article
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: How markers of β-cell loss may assist.
- Published in:
- Journal of Translational Medicine, 2012, v. 10, n. 1, p. 214, doi. 10.1186/1479-5876-10-214
- By:
- Publication type:
- Article
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 5, p. 1167, doi. 10.1111/cts.13235
- By:
- Publication type:
- Article
Structurally‐engineered fatty acid 1024 (SEFA‐1024) improves diet‐induced obesity, insulin resistance, and fatty liver disease.
- Published in:
- Lipids, 2022, v. 57, n. 4, p. 241, doi. 10.1002/lipd.12351
- By:
- Publication type:
- Article
1813-P: Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1813-P
- By:
- Publication type:
- Article
1810-P: Triple Combination Therapy of GLP-1 Receptor Agonist Semaglutide with an FXR Agonist and AC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1810-P
- By:
- Publication type:
- Article
2020-P: Comparable Disease Progression in GAN and AMLN Diet-Induced Obese Mouse Models of Biopsy-Confirmed Nonalcoholic Steatohepatitis.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-2020-P
- By:
- Publication type:
- Article
Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
- Published in:
- BMC Gastroenterology, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12876-024-03141-x
- By:
- Publication type:
- Article
Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
- Published in:
- BMC Gastroenterology, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12876-024-03141-x
- By:
- Publication type:
- Article